Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 20/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 18/20 | 1.00 |
| ▸ | PTGER1 | P34995 | 2/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 2/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 2/20 | 1.00 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 1.00 |
| ▸ | PTGER4 | P35408 | 1/20 | 1.00 |
| ▸ | PTGFR | P43088 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13629404 | 1.00 | PTGDR (1.00) | PTGDRTBXA2RPTGER1PTGER3PTGER2 | |
| SCHEMBL990528 | 1.00 | PTGDR (1.00) | PTGDRTBXA2RPTGER1PTGER3PTGER2 | |
| SCHEMBL4548353 | 1.00 | PTGDR (1.00) | PTGDRTBXA2RPTGER1PTGER3PTGER2 | |
| SCHEMBL8260383 | 0.95 | PTGDR (0.90) | PTGDRTBXA2RPTGER1PTGER3PTGER2 | |
| SCHEMBL12808618 | 0.93 | PTGDR (0.86) | PTGDRTBXA2RPTGER1PTGER3PTGER2 | |
| SCHEMBL14401189 | 0.92 | PTGDR (0.84) | PTGDRTBXA2RPTGER1PTGER3PTGER2 | |
| SCHEMBL13635024 | 0.92 | PTGDR (0.84) | PTGDRTBXA2RPTGER1PTGER3PTGER2 | |
| SCHEMBL13176191 | 0.90 | PTGDR (0.81) | PTGDRTBXA2RPTGER1PTGER3PTGER2 | |
| SCHEMBL13176193 | 0.90 | PTGDR (0.81) | PTGDRTBXA2RPTGER1PTGER3PTGER2 | |
| SCHEMBL13629405 | 0.88 | PTGDR (0.79) | PTGDRTBXA2RPTGER1PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9889082-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-13 | — | — | US | disclosed |
| US-7618979-B2 | Pyridopyrrolizine and pyridoindolizine derivatives | MERCK FROSST CANADA LTD. (CA) | 2009-11-17 | — | — | US | disclosed |
| US-7618979-B2 | Pyridopyrrolizine and pyridoindolizine derivatives | MERCK FROSST CANADA LTD. (CA) | 2009-11-17 | — | — | US | disclosed |
| US-20090258892-A1 | FUSED PYRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090258892-A1 | FUSED PYRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| WO-2007002557-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258892-A1 | FUSED PYRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ACE, ACE2, AGTR2 | PTGDR 509/4885TBXA2R 434/4885PTGER1 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.